Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.

Correspondence: Compound 17b and formyl peptide receptor biased agonism in relation to cardioprotective effects in ischaemia-reperfusion injury.

Cilibrizzi A.

Nat Commun. 2018 Feb 7;9(1):531. doi: 10.1038/s41467-017-02654-2. No abstract available.

2.

Novel ureidopropanamide based N-formyl peptide receptor 2 (FPR2) agonists with potential application for central nervous system disorders characterized by neuroinflammation.

Stama ML, ƚlusarczyk J, Lacivita E, Kirpotina LN, Schepetkin IA, Chamera K, Riganti C, Perrone R, Quinn MT, Basta-Kaim A, Leopoldo M.

Eur J Med Chem. 2017 Dec 1;141:703-720. doi: 10.1016/j.ejmech.2017.09.023. Epub 2017 Sep 18.

PMID:
29102463
3.

4-Aroyl-3-hydroxy-5-phenyl-1H-pyrrol-2(5H)-ones as N-formyl peptide receptor 1 (FPR1) antagonists.

Kirpotina LN, Schepetkin IA, Khlebnikov AI, Ruban OI, Ge Y, Ye RD, Kominsky DJ, Quinn MT.

Biochem Pharmacol. 2017 Oct 15;142:120-132. doi: 10.1016/j.bcp.2017.07.004. Epub 2017 Jul 8.

PMID:
28690139
4.

2-Arylacetamido-4-phenylamino-5-substituted pyridazinones as formyl peptide receptors agonists.

Vergelli C, Schepetkin IA, Ciciani G, Cilibrizzi A, Crocetti L, Giovannoni MP, Guerrini G, Iacovone A, Kirpotina LN, Khlebnikov AI, Ye RD, Quinn MT.

Bioorg Med Chem. 2016 Apr 8. pii: S0968-0896(16)30253-X. doi: 10.1016/j.bmc.2016.04.019. [Epub ahead of print]

5.

Core chemotype diversification in the HIV-1 entry inhibitor class using field-based bioisosteric replacement.

Tuyishime M, Lawrence R, Cocklin S.

Bioorg Med Chem Lett. 2016 Jan 1;26(1):228-34. doi: 10.1016/j.bmcl.2015.10.080. Epub 2015 Oct 27.

6.

The role of formylated peptides and formyl peptide receptor 1 in governing neutrophil function during acute inflammation.

Dorward DA, Lucas CD, Chapman GB, Haslett C, Dhaliwal K, Rossi AG.

Am J Pathol. 2015 May;185(5):1172-84. doi: 10.1016/j.ajpath.2015.01.020. Epub 2015 Mar 17. Review.

7.

Novel 3-(1H-indol-3-yl)-2-[3-(4-methoxyphenyl)ureido]propanamides as selective agonists of human formyl-peptide receptor 2.

Lacivita E, Schepetkin IA, Stama ML, Kirpotina LN, Colabufo NA, Perrone R, Khlebnikov AI, Quinn MT, Leopoldo M.

Bioorg Med Chem. 2015 Jul 15;23(14):3913-24. doi: 10.1016/j.bmc.2014.12.007. Epub 2014 Dec 13.

8.

Discovery and optimization of novel small-molecule HIV-1 entry inhibitors using field-based virtual screening and bioisosteric replacement.

Tuyishime M, Danish M, Princiotto A, Mankowski MK, Lawrence R, Lombart HG, Esikov K, Berniac J, Liang K, Ji J, Ptak RG, Madani N, Cocklin S.

Bioorg Med Chem Lett. 2014 Dec 1;24(23):5439-45.

9.

Antagonism of human formyl peptide receptor 1 (FPR1) by chromones and related isoflavones.

Schepetkin IA, Kirpotina LN, Khlebnikov AI, Cheng N, Ye RD, Quinn MT.

Biochem Pharmacol. 2014 Dec 15;92(4):627-41. doi: 10.1016/j.bcp.2014.09.027. Epub 2014 Oct 17.

10.

Design, synthesis and characterization of fMLF-mimicking AApeptides.

Hu Y, Cheng N, Wu H, Kang S, Ye RD, Cai J.

Chembiochem. 2014 Nov 3;15(16):2420-6. doi: 10.1002/cbic.201402396. Epub 2014 Sep 15.

11.

Rehabilitating drug-induced long-QT promoters: in-silico design of hERG-neutral cisapride analogues with retained pharmacological activity.

Durdagi S, Randall T, Duff HJ, Chamberlin A, Noskov SY.

BMC Pharmacol Toxicol. 2014 Mar 8;15:14. doi: 10.1186/2050-6511-15-14.

12.

Structural determinants for the interaction of formyl peptide receptor 2 with peptide ligands.

He HQ, Troksa EL, Caltabiano G, Pardo L, Ye RD.

J Biol Chem. 2014 Jan 24;289(4):2295-306. doi: 10.1074/jbc.M113.509216. Epub 2013 Nov 27. Erratum in: J Biol Chem. 2014 Feb 21;289(8):4814.

13.

Ligand-specific conformational change of the G-protein-coupled receptor ALX/FPR2 determines proresolving functional responses.

Cooray SN, Gobbetti T, Montero-Melendez T, McArthur S, Thompson D, Clark AJ, Flower RJ, Perretti M.

Proc Natl Acad Sci U S A. 2013 Nov 5;110(45):18232-7. doi: 10.1073/pnas.1308253110. Epub 2013 Oct 9.

14.

Selective agonists and antagonists of formylpeptide receptors: duplex flow cytometry and mixture-based positional scanning libraries.

Pinilla C, Edwards BS, Appel JR, Yates-Gibbins T, Giulianotti MA, Medina-Franco JL, Young SM, Santos RG, Sklar LA, Houghten RA.

Mol Pharmacol. 2013 Sep;84(3):314-24. doi: 10.1124/mol.113.086595. Epub 2013 Jun 20.

15.

Distinct signaling cascades elicited by different formyl peptide receptor 2 (FPR2) agonists.

Cattaneo F, Parisi M, Ammendola R.

Int J Mol Sci. 2013 Apr 2;14(4):7193-230. doi: 10.3390/ijms14047193. Review.

16.

3-(1H-indol-3-yl)-2-[3-(4-nitrophenyl)ureido]propanamide enantiomers with human formyl-peptide receptor agonist activity: molecular modeling of chiral recognition by FPR2.

Schepetkin IA, Kirpotina LN, Khlebnikov AI, Leopoldo M, Lucente E, Lacivita E, De Giorgio P, Quinn MT.

Biochem Pharmacol. 2013 Feb 1;85(3):404-16. doi: 10.1016/j.bcp.2012.11.015. Epub 2012 Dec 3.

17.

Annexin A1 interaction with the FPR2/ALX receptor: identification of distinct domains and downstream associated signaling.

Bena S, Brancaleone V, Wang JM, Perretti M, Flower RJ.

J Biol Chem. 2012 Jul 13;287(29):24690-7. doi: 10.1074/jbc.M112.377101. Epub 2012 May 18.

18.

Synthesis, enantioresolution, and activity profile of chiral 6-methyl-2,4-disubstituted pyridazin-3(2H)-ones as potent N-formyl peptide receptor agonists.

Cilibrizzi A, Schepetkin IA, Bartolucci G, Crocetti L, Dal Piaz V, Giovannoni MP, Graziano A, Kirpotina LN, Quinn MT, Vergelli C.

Bioorg Med Chem. 2012 Jun 15;20(12):3781-92. doi: 10.1016/j.bmc.2012.04.043. Epub 2012 Apr 27.

19.

Sublytic concentrations of Staphylococcus aureus Panton-Valentine leukocidin alter human PMN gene expression and enhance bactericidal capacity.

Graves SF, Kobayashi SD, Braughton KR, Whitney AR, Sturdevant DE, Rasmussen DL, Kirpotina LN, Quinn MT, DeLeo FR.

J Leukoc Biol. 2012 Aug;92(2):361-74. doi: 10.1189/jlb.1111575. Epub 2012 May 11.

20.

Group A Streptococcus secreted esterase hydrolyzes platelet-activating factor to impede neutrophil recruitment and facilitate innate immune evasion.

Liu M, Zhu H, Li J, Garcia CC, Feng W, Kirpotina LN, Hilmer J, Tavares LP, Layton AW, Quinn MT, Bothner B, Teixeira MM, Lei B.

PLoS Pathog. 2012;8(4):e1002624. doi: 10.1371/journal.ppat.1002624. Epub 2012 Apr 5.

Supplemental Content

Support Center